Treating Non–Small-Cell Lung Cancer with EGFR Mutations with Osimertinib as Adjuvant Therapy

Web Exclusives —April 2, 2021

Categories:

Lung Cancer

The US Food and Drug Administration approved osimertinib for adjuvant therapy after tumor resection in patients with non–small-cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations that have been detected by an approved test.

In ADAURA, a randomized, double-blind, placebo-controlled clinical trial, adjuvant therapy with osimertinib demonstrated efficacy in patients with EGFR exon 19 deletions or exon 21 L858R mutation–positive NSCLC who had complete tumor resection, with or without prior adjuvant chemotherapy.

Qualified patients who had resectable tumors (stage IB-IIIA) and predominantly nonsquamous histology as well as EGFR exon 19 deletions or exon 21 L858R mutations were identified prospectively from tumor tissue in a central laboratory using a test for EGFR mutation. Patients (N = 682) were randomized (1:1) to receive either oral once-daily osimertinib (80 mg) or placebo postsurgical procedure and standard adjuvant chemotherapy, if provided.

In patients with stage II to IIIA NSCLC, disease-free survival was the major efficacy outcome measure; this was assessed by investigator determination. Median disease-free survival was not reached in patients in the osimertinib arm, contrasted with patients in the placebo arm (19.6 months).

In the overall study population, disease-free survival was a secondary efficacy outcome measure; the median was not reached in the osimertinib arm, contrasted with 27.5 months in the placebo arm.

For adjuvant treatment of early-stage NSCLC, the recommended once-daily osimertinib dose is 80 mg orally with or without food, until disease recurrence, unacceptable toxicity, or for up to 3 years.1

In patients receiving osimertinib, the most common (>20%) adverse reactions, including laboratory abnormalities, were anemia, cough, diarrhea, dry skin, fatigue, leukopenia, lymphopenia, musculoskeletal pain, nail toxicity, neutropenia, rash, stomatitis, and thrombocytopenia.

Source

US Food and Drug Administration. FDA approves osimertinib as adjuvant therapy for non-small cell lung. www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-osimertinib-adjuvant-therapy-non-small-cell-lung-cancer-egfr-mutations. Published 2021. Accessed March 17, 2021.

Reference

  1. Tagrisso (osimertinib) [package insert]. AstraZeneca. Updated 2020. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf. Accessed March 17, 2021.
Related Articles
American Cancer Society Cancer Action Network Releases Recommendations to Increase Cancer Biomarker Testing
Web Exclusives
The American Cancer Society Cancer Action Network has published data that demonstrate there are multiple barriers to biomarker testing access and released recommendations that address these barriers.
Sotorasib Demonstrates Efficacy in CodeBreaK 100 Phase 2 Study Results
Web Exclusives
Sotorasib has shown promising antitumor activity in phase 2 of a clinical trial of patients with heavily treated advanced NSCLC.
Results of an International Study Identify Barriers to Molecular Testing in NSCLC
Web Exclusives
Recently released survey responses identified multiple barriers to, and dissatisfaction with, the current state of molecular testing in lung cancer.
Last modified: April 2, 2021

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code